Welcome to our dedicated page for BillionToOne news (Ticker: BLLN), a resource for investors and traders seeking the latest updates and insights on BillionToOne stock.
BillionToOne, Inc. reports developments in molecular diagnostics, with news centered on its QCT molecular counting platform, prenatal testing franchise and Northstar oncology liquid biopsy portfolio. Recurring updates cover financial results, revenue guidance, test volumes, product launches and leadership changes tied to the company’s clinical testing operations.
The company’s prenatal news includes UNITY products for non-invasive prenatal testing, fetal antigen testing and Unity Confirm, a circulating fetal cell-based confirmation test. Oncology updates focus on Northstar Select, Northstar Response and add-on liquid biopsy applications such as Northstar PGx and Northstar Select CH for therapy-selection and related clinical insights.
BillionToOne (Nasdaq: BLLN) completed an upsized initial public offering of 4.6 million shares of Class A common stock at $60 per share, generating approximately $273.1 million in aggregate gross proceeds. The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025.
Gunderson Dettmer represented BillionToOne across multiple financings from Series A through late-stage rounds and advised on the public listing; J.P. Morgan, Piper Sandler, Jefferies and William Blair acted as joint book-running managers, with Stifel, Wells Fargo Securities and BTIG also serving as book-running managers.
BillionToOne (Nasdaq: BLLN) priced an upsized initial public offering of 4,551,100 shares of Class A common stock at $60.00 per share, with expected gross proceeds of approximately $273.1 million before underwriting discounts and expenses.
The underwriters have a 30-day option to purchase up to an additional 682,665 shares at the IPO price. Shares are expected to begin trading on the Nasdaq Global Select Market on November 6, 2025, and the offering is expected to close on November 7, 2025, subject to customary closing conditions.
BillionToOne (NASDAQ: BLLN) launched the roadshow for a proposed initial public offering of 3,846,000 shares of Class A common stock, with a 30-day underwriter option to purchase up to 576,900 additional shares.
The initial public offering price is currently expected to be between $49.00 and $55.00 per share. BillionToOne has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker BLLN. J.P. Morgan, Piper Sandler, Jefferies and William Blair are joint book-running managers.
A registration statement on Form S-1 has been filed with the SEC but has not yet become effective; offers or sales may not occur before effectiveness.